Analyst picks & changes

BioChem Pharma Inc.

(BCHE), Laval, Quebec

Business: Infectious diseases/AIDS

Montgomery Securities analyst David Crossen raised his 1997

3TC

sales estimate from $760 million from $630 million, and his 1998 estimate to $1.04

Read the full 335 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE